Here are the DEF 14A proxy statements from Cumberland Pharmaceuticals Inc (CPIX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CPIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPIX filings page.
Cumberland Pharmaceuticals Inc. has issued its definitive proxy for the 2026 Annual Meeting, to be held April 21, 2026 at its Nashville headquarters. Shareholders will vote on electing two Class I directors (Kenneth Krogulski and Caroline Young), ratifying Carr, Riggs & Ingram, L.L.C. as auditor for 2026, an advisory “say‑on‑pay” vote on executive compensation, and an advisory vote on how often to hold future say‑on‑pay votes.
The Board recommends voting for all proposals and for holding say‑on‑pay votes every three years. The company discloses 2025 executive pay, highlights 20% revenue growth with higher adjusted earnings and cash flow, and reports a CEO pay ratio of 10:1, with the CEO beneficially owning 38.43% of outstanding common stock.